Vibrynt Inc.’s adjustable VIBRYNT PREVAIL Implant System is a saline-filled, silicone bladder designed to limit the stomach's ability to expand beyond the size of a small tube, and thus limit food consumption and calorie intake. The permanent implant is placed laparoscopically on the top of but still outside the stomach, and is designed to occupy the space that the stomach would normally expand to as a meal is eaten. Unlike the currently available surgical options, with the Vibrynt system there is no altering of the gastrointestinal anatomy and there are no restrictions on the types of healthy foods patients can eat.
[Vibrynt Inc.]
701 Galveston DriveRedwood City, CA 94063
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.
While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.
Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.
